[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"celiac-disease-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:celiac-disease-in-children":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,42,68,98,125,211,234,255,275,295,325,350,375,405,429,452,472],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100543465","gf-nourish-gluten-free-nutrition-optimization-through-ultra-processed-food-reduction-and-improved-strategies-for-health-100543465",false,"NCT06356220","GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)","GF-NOURISH","Inclusion Criteria:\n\n* Age 2-18 years of age with recent celiac disease diagnosis\n\nExclusion Criteria:\n\n* Allergic to \\\u003C3 of the top 8 food allergens\n* Co-morbid conditions treated with dietary modifications or that influence nail arsenic values","ALL","2 Years","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The investigators propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study to demonstrate the feasibility and success of a nutritional education program focused on naturally occurring gluten-free foods and minimizing ultra-processed gluten-free foods. The investigators hypothesize that nutritional educational (GF-NOURISH) intervention will have multiple health benefits",[27,28],"Celiac Disease in Children","Nutrition Disorder, Child","RECRUITING","2026-05-08",{"date":32,"type":33},"2026-05-12","ACTUAL",{"date":35,"type":33},"2025-04-29",{"date":37,"type":21},"2026-12",{"name":39,"class":40},"Boston Children's Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100636276","efficacy-of-oral-sucrosomial-iron-supplementation-in-children-with-celiac-disease-and-iron-deficiency-or-anemia-100636276","NCT07563582","Efficacy of Oral Sucrosomial Iron Supplementation in Children With Celiac Disease and Iron Deficiency or Anemia","Efficacy of Oral Sucrosomial Iron Supplementation in Children With Celiac Disease and Iron Deficiency or Anemia: a Double-blind, Randomized, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Diagnosis of CD according to the current European ESPGHAN guidelines (clinical or histological) with confirmed hypoferritinemia or iron deficiency anemia.\n2. Age at diagnosis of CD between 8 and 18 years (inclusive).\n3. Absence of oral martial supplementation in the 30 days before the diagnosis and intravenous martial supplementation in the 90 days prior to the diagnosis of CD.\n4. Patients who have not already started GFD before diagnosis.\n5. Exclusion of other causes of anemia.\n6. Patients (and parents\u002Flegal guardian) able to understand and willing to participate in the study, with collaborative attitude.\n7. Informed consent release by both parents\u002Flegal guardian.\n\nExclusion Criteria:\n\n1. Potential celiac disease.\n2. Hb \\\u003C 8 g\u002FdL at screening\n3. Other causes of anemia, hemoglobinopathies or coagulopathies.\n4. Active bleeding or surgery or major trauma in the last 6 months.\n5. Other inflammatory diseases, neoplasms or IgE mediated food allergies\n6. Syndromes or presence of vascular malformations\n7. Pregnant or lactating patients (based on self-certification by the parents and by the patient, where applicable)\\*\n8. Patients with known or suspected allergy or hypersensitivity to the study products or any of their excipients.\n9. Taking oral iron-based medications in the 30 days prior to diagnosis and intravenous iron-based medications in the 90 days prior to diagnosis.\n10. Use of other investigational drug(s) within 30 days before study entry or during the study.\n11. Any other condition, illness or treatment that in the Investigator's opinion does not make the patient suitable for the study.\n\n    * Self-certification of non-pregnancy status is considered sufficient given that the product under study is a safe and well-tolerated dietary supplement that has already been tested in pregnant women.","8 Years",{"count":51,"type":21},60,[24],"Celiac disease in children is frequently associated with iron deficiency and\u002For iron deficiency anemia due to intestinal malabsorption and chronic inflammation. Although a gluten-free diet is the standard treatment and can restore iron balance over time, there is currently no clear evidence or consensus on the role and timing of iron supplementation in pediatric patients at diagnosis.\n\nGiven the potential impact of anemia on growth and neurodevelopment, strategies that enable a faster correction of iron deficiency are clinically relevant. Sucrosomial® iron has shown improved absorption and gastrointestinal tolerability compared to conventional oral iron in adult celiac patients.\n\nThis study aims to evaluate whether Sucrosomial® iron supplementation, in addition to a gluten-free diet, is more effective and safe than diet alone in achieving a faster normalization of hemoglobin and iron stores in children with newly diagnosed celiac disease.\n\nThe primary objective of this randomized, double-blind, placebo-controlled, parallel-group study is to assess whether oral supplementation with Sucrosomial® iron, when added to a gluten-free diet (GFD), accelerates the normalization of iron stores and hemoglobin levels compared with GFD alone in school-age children and adolescents newly diagnosed with celiac disease presenting with hypoferritinemia and\u002For iron deficiency anemia.\n\nTarget Study Population: Children and adolescents with celiac disease and iron deficiency or anemia due to iron deficiency.\n\nStudy Duration Total study duration (per patient) will be about 6 months; total treatment duration (per patient) will be 6 months.\n\nNumber of Patients: 60 planned Two typologies of patients will be included: with hypoferritinemia and with anemia due to iron deficiency.\n\nThe randomization process will be stratified, so that:\n\n* 15 patients with hypoferritinemia receive active treatment and 15 patients receive placebo;\n* 15 patients with anemia due to iron deficiency receive active treatment and 15 patients receive placebo.\n\nThe age of patients will also be considered for the randomization (to assign the correct number of product bottles).",[27,55,56],"Anemia","Iron Deficiencies",[58],"Iron deficiency\u002Fanemia due to iron deficiency in CD children and adolescents","2026-04-29",{"date":61,"type":33},"2026-05-04",{"date":63,"type":33},"2025-12-23",{"date":65,"type":21},"2027-09",{"name":67,"class":40},"Istituto Giannina Gaslini",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100531962","liver-steatosis-in-pediatric-cd-patients-100531962","NCT06206616","Liver Steatosis in Pediatric CD Patients","Liver Steatosis in Pediatric Celiac Disease Patients: Exploring the Epidemiological and Pathophysiological Features of an Underestimated Condition","Inclusion Criteria:\n\n* Age \\>1 and \\\u003C14 years\n* Celiac Disease diagnosis according European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria\n\nExclusion Criteria:\n\n* age \\\u003C1 and \\>14 years;\n* self-exclusion of gluten\u002Fwheat from the diet and refusal to reintroduce it, for diagnostic purposes, before entering the study;\n* bacterial and\u002For parasitic infections;\n* diagnosis of chronic inflammatory intestinal diseases and other organic pathologies affecting the digestive system (for example, serious liver diseases), nervous system diseases, immunological deficits and impairments that limit physical activity;\n* diagnosis of cancer\n* patients undergoing chemotherapy and\u002For radiotherapy.","1 Year","14 Years",{"count":78,"type":21},91,"OBSERVATIONAL","Celiac disease (CD) is an autoimmune enteropathy triggered by the intake of gluten, characterized by a genetic predisposition. Although, CD is often associated with malabsorption symptoms, a growing number of affected subjects are overweight or frankly obese. One of the conditions that is most frequently detected in pauci\u002Fasymptomatic subjects is an increase in transaminases, which often regresses completely after the start of GFD.\n\nMore recently, a specific liver disorder has shown a certain relevance in adult patients suffering from CD, so much so that the European Society for the Study of Coeliac Disease (ESsCD) has cited it among the possible comorbidities which should be screened in CD subjects: Non-Alcoholic Fatty Liver Disease (NAFLD).\n\nIn adults, a non-random association between CD and NAFLD has been demonstrated, showing a CD prevalence rate of 2-14% among patients with NAFLD. Few studies have focused on this same aspect in pediatric age, reporting contrasting data.\n\nSeveral factors have been advocated as putative responsible of association between CD and NAFLD: dietary imbalances, intestinal mucosa permeability impairment, alterations of the intestinal microbiota.\n\nThe objectives of this study are:\n\n1. define, retrospectively, the prevalence of NAFLD in a pediatric population affected by CD and study its possible association with GFD.\n2. define the possible role of the intestinal permeability alteration and\u002For the intestinal mucosa damage and\u002For the proinflammatory status in the development of NAFLD in children affected by CD.",[27,82],"Non-Alcoholic Fatty Liver Disease",[84,82,85,86,87],"Celiac Disease","Intestinal Permeability","Inflammatory Cytokines","Children","2026-04-27",{"date":90,"type":33},"2026-05-01",{"date":92,"type":21},"2027-11-01",{"date":94,"type":21},"2028-09-30",{"name":96,"class":40},"University of Palermo",2,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":49,"maxAge":18,"enrollmentInfo":105,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100622390","effect-of-adherence-to-a-gluten-free-diet-on-cognitive-and-motor-dual-task-performance-in-adolescents-diagnosed-with-celiac-disease-100622390","NCT07382999","Effect of Adherence to a Gluten-Free Diet on Cognitive and Motor Dual-Task Performance in Adolescents Diagnosed With Celiac Disease","Inclusion Criteria:\n\n* Participants aged between 8 and 18 years with a serologically confirmed diagnosis of celiac disease\n* Who have been followed for at least six months after diagnosisn\n* For whom written informed consent has been obtained from both the participant and their parent\u002Flegal guardian, will be included in the study.\n* The healthy control group will consist of individuals in the same age range with no history of chronic neurological, psychiatric, or gastroenterological diseases.\n\nExclusion Criteria:\n\n* Will include the presence of an acute infection or systemic disease\n* Diagnosed neurological disorders (such as epilepsy or cerebral palsy);\n* A history of severe psychiatric disorders; conditions that may interfere with test administration, including visual, hearing, or ambulatory impairments\n* Initiation of psychotropic medication or changes in the current dosage within the past four weeks; the presence of unstable metabolic or endocrine disorders\n* Failure to obtain the required informed consent for participation.",true,{"count":106,"type":21},82,"The aim of this cross-sectional observational study is to comprehensively examine the effects of adherence to a gluten-free diet on cognitive, motor, and psychosocial functions in adolescents aged 8-18 years diagnosed with celiac disease. In this context, dual-task gait performance, cognitive processing speed and attention, working memory and executive functions, muscle strength, quality of life, and fatigue levels of individuals with celiac disease who are adherent or non-adherent to a gluten-free diet will be compared with those of healthy peers. In addition, sleep patterns, pubertal development, socioeconomic indicators, and serological markers will be taken into account to evaluate the unique effects of diet adherence on neurocognitive and functional outcomes. All assessments will be conducted in accordance with a predefined standardized protocol. The order of measurement instruments will be randomized to minimize potential bias. Inclusion criteria will consist of being between 8 and 18 years of age, having a celiac disease diagnosis confirmed by serology, being followed with this diagnosis for at least six months, and obtaining written informed consent from both the participant and their parent\u002Fguardian. For the healthy control group, participants must be within the same age range and have no history of chronic neurological, psychiatric, or gastroenterological conditions. Data analysis will be performed using SPSS",[27,109],"Celiac Disease in Adolescents",[111,112,113,114],"Celiac","Cognitive function","10 MWT","TMT A-B","NOT_YET_RECRUITING","2026-02-01",{"date":118,"type":33},"2026-02-03",{"date":120,"type":21},"2026-02-12",{"date":122,"type":21},"2026-08-15",{"name":124,"class":40},"Inonu University",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":134,"studyType":79,"phases":4,"briefSummary":135,"conditions":136,"keywords":179,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":41},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform",{"count":133,"type":21},10000,"10 Years","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[137,138,139,140,141,142,143,84,27,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[155,180,181,182,183,184,185,186,187,188,138,189,190,191,192,193,157,194,195,196,197,198,199,200,201],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":204,"type":33},"2026-01-22",{"date":206,"type":33},"2023-07-05",{"date":208,"type":21},"2030-12-31",{"name":210,"class":40},"Brain Inflammation Collaborative",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":104,"sex":16,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":4},"100614893","eating-behaviors-in-children-and-adolescents-withwithout-celiac-disease-100614893","NCT07285512","Eating Behaviors in Children and Adolescents With\u002FWithout Celiac Disease","Eating Behaviors in Children and Adolescents With\u002FWithout Celiac Disease: A Cross-Sectional and Longitudinal Study","Inclusion Criteria:\n\nCeliac Disease Group (Cases)\n\n* Adolescents aged 11 to 17 years\n* Confirmed diagnosis of celiac disease according to the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) criteria (positive serology and\u002For duodenal biopsy)\n* Ability to understand and complete questionnaires in Italian\n* For the longitudinal cohort: diagnosis \\\u003C 6 months prior to enrollment\n\nHealthy Control Group\n\n* Adolescents aged 11 to 17 years\n* No diagnosis of celiac disease\n* Ability to understand and complete questionnaires in Italian\n\nExclusion Criteria:\n\n* Significant cognitive impairment or developmental disorders preventing questionnaire completion\n* Inadequate understanding of the Italian language\n* Refusal or inability to provide assent\u002Fconsent","11 Years","17 Years",{"count":221,"type":21},300,"This observational study investigates the prevalence and severity of disordered eating behaviors in adolescents aged 11-17 years with celiac disease. Participants complete validated self-report questionnaires (Youth Eating Disorder Examination Questionnaire, YEDE-Q, and Parent Eating Disorder Examination Questionnaire, PEDE-Q) and a structured clinical form. A healthy control group, matched by age and sex, is included for comparison. A longitudinal sub-cohort diagnosed with celiac disease \\\u003C6 months prior will be followed at 6, 12, and 24 months to evaluate changes in eating psychopathology and associated clinical variables.",[27,224],"Eating Behaviors","2025-12-12",{"date":227,"type":33},"2025-12-16",{"date":229,"type":21},"2025-12-15",{"date":231,"type":21},"2028-12-15",{"name":233,"class":40},"IRCCS San Raffaele",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":4},"100607770","dietary-intervention-using-a-gluten-free-app-to-improve-tracking-adherence-and-learningdigital-study-100607770","NCT07192874","Dietary Intervention Using a Gluten-free App to Improve Tracking, Adherence, and Learning(DIGITAL) Study","DIGITAL Study: Evaluating \"MyMedDiary\" as a Tool for Improving Gluten-Free Diet Adherence and Knowledge in Children With Newly Diagnosed Celiac Disease","DIGITAL","Inclusion Criteria:\n\n* Children (2-18 years of age) with a new diagnosis of celiac disease\n\nExclusion Criteria:\n\n* Children allergic to more than 2 of the top 8 food allergens and\u002For with co-morbid conditions treated with dietary modifications will be excluded",{"count":20,"type":21},[24],"With rising incidence of celiac disease(CeD) (3% of population), there is an urgent need for practical, efficient and usable application that can feedback to families and providers about their ultra-processed gluten-free food (UPGFF) consumption as well as to help families identify where they may be having unintentional gluten exposure. The investigators propose to use MyMedDiary, a researcher driven platform dedicated to streamline and enhance dietary data collection, to first validate that it can accurately and efficiently identify gluten-free foods which are ultra-processed. The investigators aim to provide feedback to families on potential sources of gluten exposure as they transition to a gluten-free diet(GFD).",[27],[247],"CELIAC","2025-09-24",{"date":250,"type":33},"2025-09-29",{"date":252,"type":21},"2026-01",{"date":65,"type":21},{"name":39,"class":40},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":262,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":271,"leadSponsor":273,"locationsCount":4},"100605024","assessment-of-the-adherence-to-a-gluten-free-diet-and-nutritional-status-of-paediatric-patients-with-coeliac-disease-100605024","NCT07157137","Assessment of the Adherence to a Gluten-free Diet and Nutritional Status of Paediatric Patients With Coeliac Disease","CD-PL","Inclusion criteria:\n\n* diagnosis of coeliac disease according to the European Society of Pediatric Gastroenterology and Nutrition (ESPGHAN) criteria,\n* age from 2 to 18 years of age,\n* gluten-free diet use for at least 6 months,\n* consent from legal guardians (and the child in case of patients ≥16 years of age) to participate in the study.\n\nExclusion criteria:\n\n* under 2 years of age and over 18 years of age,\n* immunoglobulin A deficiency,\n* inflammatory bowel diseases,\n* gastrointestinal bleeding or other active bleeding,\n* gastric and\u002For duodenal ulcers,\n* liver failure,\n* heart failure according to the NYHA II-IV scale,\n* acute and chronic renal failure,\n* cancer,\n* after hematopoietic stem cell transplantation,\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients ≥ 16 years of age).",{"count":263,"type":21},140,"Although a gluten-free diet (GFD) is essential for patients with coeliac disease (CD), many do not follow it strictly. Exposure to gluten causes villous atrophy, can deteriorate nutritional status, and can lead to deficiencies. The ESPGHAN recommends combining multiple methods to assess GFD adherence. The Celiac Dietary Adherence Test (CDAT) and measuring the gluten immunogenic peptide in urine (uGIP) or stool (sGIP) were suggested.\n\nThis study aims to evaluate and compare the usefulness of an adapted CDAT, the rapid tests for detecting uGIP and sGIP, for assessing adherence to a GFD in children with CD. Additionally, we will assess these children's nutritional status.\n\nPatients, aged 2-18 years, diagnosed with CD, who have been on a GFD for at least 6 months, will be included. Clinical characteristics and anthropometric measurements will be recorded. The adapted CDAT form will be applied. A single urine and stool samples will be collected immediately, and rapid tests for the detection of GIP will be performed. The serum levels of anti-transglutaminase antibodies (IgA), albumin, ferritin, folate, vitamins B12, A, E, 25-OH vitamin D, blood count and lipid profile will be measured.",[27,266],"Gluten-free Diet","2025-08-27",{"date":269,"type":33},"2025-09-05",{"date":252,"type":21},{"date":272,"type":21},"2027-08",{"name":274,"class":40},"Medical University of Warsaw",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":283,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":294,"locationsCount":4},"100603871","validation-of-the-cdat-in-the-polish-paediatric-population-100603871","NCT07142148","Validation of the CDAT in the Polish Paediatric Population","Validation of the Celiac Dietary Adherence Test in the Polish Paediatric Population","CD-PL-CDAT","Inclusion Criteria:\n\n* diagnosis of coeliac disease (CD) according to the European Society of Pediatric Gastroenterology and Nutrition (ESPGHAN) criteria,\n* age from 2 to 18 years of age,\n* consent from legal guardians (and the child in case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria:\n\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients ≥ 16 years of age).",{"count":284,"type":21},20,"The English version of the Celiac Dietary Adherence Test (CDAT) will be translated into Polish using the \"forward-backwards-forward\" translation model, with the author's consent (already obtained by the applicants).\n\nThe Polish translation will be performed by two native bilingual speakers of Polish and English. Both translations will be compared and standardised. The Polish version will then be translated into English by two native bilingual speakers of English who are unfamiliar with the original English version. The translation and original will be compared to clarify discrepancies and ensure conceptual equivalence between the versions. The agreed-upon translation will be culturally adapted, if necessary. The items will be reviewed by five experts, and an I-CVI of at least 0.78 will be considered satisfactory content validity.\n\nIn the next step, 10 coeliac disease (CD) patients aged 10 years and older and 10 caregivers\u002Fparents of CD patients under 10 years of age will be asked to rate the clarity of each statement on a Likert scale \\[1 = unclear to 5 = very clear\\]. Questions with a mean score \\\u003C4.0 will be rephrased and re-evaluated.\n\nInternal consistency analysis using Cronbach's alpha and the mean inter-item correlation (AIC) will be used to assess reliability. Convergent validity will be assessed by comparing scale scores with serological marker levels. Confirmatory factor analysis (CFA) will be conducted, taking into account the SRMR fit index.",[287,27],"Coeliac Disease","2025-08-26",{"date":290,"type":33},"2025-09-03",{"date":292,"type":21},"2026-09",{"date":272,"type":21},{"name":274,"class":40},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":313,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":97},"100455362","immune-responses-to-gluten-100455362","NCT05209568","Immune Responses to Gluten","Changes in Serum IL-2 Levels Following a Single Oral Dose of Gluten","Inclusion Criteria:\n\n1. On a gluten-free diet for ≥ 4 weeks\n2. Willing to consume gluten for research\n3. For the celiac disease arm, diagnosis confirmed by serology and\u002For histology\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Wheat allergy\n3. Type 1 diabetes\n4. BMI z-score \\\u003C -2\n5. History of more than minimal symptoms following gluten exposure on a gluten-free diet\n6. Comorbid condition that in the opinion of the investigator would interfere with study participation or would confound study results","101 Years",{"count":304,"type":21},400,[24],"This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.",[84,308,309,310,311,312,27],"Malabsorption Syndromes","Digestive System Disease","Intestinal Disease","Gastrointestinal Diseases","Gluten Sensitivity",[314,315,316],"gluten","cytokine","T cell immune response","2025-04-18",{"date":319,"type":33},"2025-04-23",{"date":321,"type":33},"2023-01-15",{"date":323,"type":21},"2029-09-30",{"name":39,"class":40},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":16,"minAge":332,"maxAge":218,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":41},"100587633","supporting-children-and-young-people-to-live-well-with-coeliac-disease-a-rct-100587633","NCT06930924","Supporting Children and Young People to Live Well With Coeliac Disease: A RCT","Evaluation of a Self-help Psychological Intervention to Support Gluten-free Diet Management, Psychological Wellbeing and Quality-of-life in Children and Young People (Aged 7-11) With Coeliac Disease","Inclusion Criteria:\n\nCaregiver(s) with a CYP between 7-11 years of age who report a diagnosis of coeliac disease Willingness to take part in a self-help psychological intervention Participant must have the ability to provide informed consent\u002Fassent. Caregiver(s) who consent to the study will still be able to take part, even if their CYP does not provide assent to complete outcome measures\n\nExclusion Criteria:\n\nFamilies participating in another intervention-based research will not be eligible Participant identified by clinical team as not appropriate (e.g. undergoing treatment for other complex difficulties) English proficiency unsuitable for participation in self-help psychological intervention and\u002F or online survey.","7 Years",{"count":334,"type":21},350,[24],"Managing a strict gluten-free diet is crucial for children and young people with coeliac disease. However, this can have adverse effects on psychological well-being and quality of life. Despite appeals from families, clinicians, and researchers, psychological support is not routinely provided to these families. A feasibility project (NCT06007898) adapted existing self-help psychological resources used for food allergy, gastrointestinal disease, and type one diabetes to cater to families dealing with coeliac disease. This feasibility randomised controlled trial was conducted with 100 families and highlighted the viability and acceptability of this self-help resource. This pilot study was conducted in consultation with caregiver(s), clinicians, and CYP living with coeliac disease. These consultations confirmed a lack of support in this area and the enthusiasm for self-help psychological interventions. We will now run a full randomised controlled trial to evaluate the effectiveness of the intervention for caregiver(s) of CYP with coeliac disease in supporting the appropriate management of the gluten-free diet, alongside psychological wellbeing.\n\nFor this trial, 172 families will complete well-being and quality of life questionnaires, along with assessments of their child's gluten-free dietary management. Families will be divided into groups receiving the psychological resources either immediately or after a five-month delay. Follow-up questionnaires will be administered at one, two, and five months for all families, regardless of intervention access. Feedback on the resources and research participation will be gathered. The expectation is that these self-help psychological resources for parents will enhance gluten-free diet management, quality of life for coeliac children and young people, and well-being for parents.",[287,27],[339,340],"Coeliac disease","celiac disease","2025-04-08",{"date":343,"type":33},"2025-04-16",{"date":345,"type":21},"2025-05-01",{"date":347,"type":21},"2026-03-01",{"name":349,"class":40},"University of Surrey",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":111,"eligibilityCriteria":356,"healthyVolunteers":104,"sex":16,"minAge":357,"maxAge":358,"enrollmentInfo":359,"targetDuration":357,"studyType":79,"phases":4,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":4},"100586334","clinical-association-between-celiac-disease-and-intussusception-in-children-100586334","NCT06914024","Clinical Association Between Celiac Disease and Intussusception in Children","Clinical Association Between Celiac Disease and Intussusception in Children Attending Assiut University Children Hospital","Inclusion Criteria:\n\nChildren aged 6 months to 18 years Diagnosed with celiac disease based on serology and biopsy Diagnosed with intussusception confirmed by imaging Parent or legal guardian provides informed consent\n\nExclusion Criteria:\n\nChildren with known gastrointestinal abnormalities other than celiac disease History of abdominal surgery Incomplete or unavailable medical records Patients on immunosuppressive therapy","6 Months","3 Years",{"count":360,"type":21},30,"Clinical association Between Celiac Disease and Intussusception in children",[27,363],"Intussusception",[365],"pediatric gastrointestinal disease","2025-04-07",{"date":368,"type":33},"2025-04-09",{"date":370,"type":21},"2025-10-01",{"date":372,"type":21},"2026-11",{"name":374,"class":40},"merna hamdy kamal mohammed",{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":16,"minAge":382,"maxAge":18,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":385,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":404},"100586896","iron-deficiency-in-pediatric-celiac-disease-diet-vs-iron-supplementation-trial-100586896","NCT06921343","Iron Deficiency in Pediatric Celiac Disease: Diet vs. Iron Supplementation Trial","Iron Deficiency Without Anemia in Children With Newly Diagnosed Celiac Disease: A Randomized, Open-Label, Controlled Trial.","Inclusion Criteria:\n\n* Children aged 18 months to 18 years\n* Newly diagnosed with celiac disease (based on ESPGHAN guidelines)\n* Ferritin levels below 15 ng\u002FdL\n* Normal hemoglobin, MCV, and MCH levels for age and sex\n\nExclusion Criteria:\n\n* IgA deficiency preventing TTG antibody monitoring\n* Potential celiac disease (positive serology with normal intestinal histology)\n* Underlying diseases that may cause anemia (e.g., Inflammatory bowel disease, eosinophilic gastrointestinal disease, certain gastritis types)\n* Diseases affecting iron absorption (e.g., Cystic Fibrosis)\n* Congenital anemia (e.g., Thalassemia, hereditary spherocytosis)\n* Prior iron supplementation (\\>14 days oral iron within 2 months or IV iron within 6 months before diagnosis)","18 Months",{"count":384,"type":21},150,[24],"This study aims to understand how to best manage iron deficiency in children newly diagnosed with celiac disease. Many children with celiac disease have low iron levels, even if they do not have anemia. While some doctors recommend iron supplements, others believe that simply following a gluten-free diet may be enough to restore iron levels naturally.\n\nIn this study, children with newly diagnosed celiac disease and low iron levels (but normal hemoglobin) will be randomly assigned to one of two groups:\n\nGluten-Free Diet Only - No additional iron supplements Gluten-Free Diet + Iron Supplementation Researchers will compare iron store levels over one year to see if iron supplements provide any additional benefit beyond the gluten-free diet alone. The study will also track possible side effects of iron supplements, such as stomach discomfort.\n\nThis study will help doctors determine the best approach to managing iron deficiency in children with celiac disease, ensuring they receive the safest and most effective treatment.",[27,388],"Iron Deficiency",[193,390,391,392,393,394],"Pediatric celiac disease","Iron deficiency","Ferritin levels","Gluten-free diet","Iron supplementation","2025-04-03",{"date":397,"type":33},"2025-04-10",{"date":399,"type":21},"2025-04",{"date":401,"type":21},"2028-12",{"name":403,"class":40},"Kaplan Medical Center",5,{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":41},"100581385","auto-antibody-dosage-from-blood-spots-for-diagnosis-of-type-1-diabetes-and-celiace-disease-100581385","NCT06849622","Auto-antibody Dosage From Blood Spots for Diagnosis of Type 1 Diabetes and Celiace Disease","CELDI","Inclusion Criteria:\n\n* Patients aged 2-13 years\n* Patients with a confirmed diagnosis of type 1 diabetes or celiac disease (positive controls) and children who do not have type 1 diabetes or celiac disease or autoantibodies associated with these pathologies (controls)\n* Obtained informed consent\n\nExclusion Criteria:\n\n* none","13 Years",{"count":414,"type":21},1500,[24],"Early diagnosis of type 1 diabetes and celiac disease is very useful, allows early therapy and prevents deaths from the onset of diabetic ketoacidosis. This is a pilot study on screening of autoantibodies of type 1 diabetes and celiac disease in tuscany patients. The study aims to evaluate the concordance between the screening results obtained using two different matrix (blood drop spots on card and serum) in the search for autoantibodies for celiac disease and for type 1 diabetes. Moreover, it will be evaluated the feasibility and acceptability of the screening on a sample of the population enrolled in the territory through the participation of pediatricians.",[27,418,419],"Diabetes Mellitus, Type I","Screening","2025-02-25",{"date":422,"type":33},"2025-02-27",{"date":424,"type":33},"2024-11-04",{"date":426,"type":21},"2026-03-30",{"name":428,"class":40},"Meyer Children's Hospital IRCCS",{"id":430,"slug":431,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":104,"sex":16,"minAge":436,"maxAge":18,"enrollmentInfo":437,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":97},"100559755","celiac-disease-and-quality-of-life-in-children-and-adolescents-celiaqlife-100559755","NCT06568263","Celiac Disease and Quality of Life in Children and Adolescents (CeliaQLife)","CeliaQLife","Inclusion Criteria:\n\n* eating a regular diet\n\nExclusion Criteria:\n\n\\-","6 Years",{"count":438,"type":21},160,"Celiac disease is a disorder commonly diagnosed during childhood. The treatment is a lifelong gluten-free diet. Both the condition and the diet can influence the children's physical and emotional well-being.\n\nThe main goal of this observational study is to learn about nutritional status in a group of children with celiac disease compared to a group of healthy children.\n\nThe nutritional assessment includes information on diet, biochemical measurement, and body composition. Quality of life will also be assessed.\n\nThe study can contribute to ensure good health and well-being in children on a gluten-free diet.",[27,441,442],"Nutritional Deficiency","Quality of Life","2024-08-20",{"date":445,"type":33},"2024-08-23",{"date":447,"type":33},"2024-08-12",{"date":449,"type":21},"2025-12-20",{"name":451,"class":40},"Oslo University Hospital",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":41},"100544119","entities-and-variables-related-to-catch-up-growth-100544119","NCT06364735","Entities and Variables Related to Catch-up Growth","Entities and Variables Related to Catch-up Growth in Pediatric Patients With Celiac Disease (CD) on a Gluten-free Diet (GFD)","Inclusion Criteria:\n\n* celiac disease diagnosis established at the V. Buzzi Children\\'s Hospital in Milan between January 2010 and December 2020, excluding the extremes, in accordance with the ESPGHAN 2012 or 2020 recommendations.\n\nExclusion Criteria:\n\n* patients with unclear or non-specific duodenal histological alterations (e.g., atrophy with unavailable or negative specific antibodies for celiac disease);\n* patients with additional chronic illnesses;\n* absence of the data required for the study;\n* patients with IgA deficiency, defined as IgA \\<20 mg\u002Fdl in children \\<3 years old or with levels that are below normal for their age.",{"count":460,"type":21},900,"A retrospective monocentric observational no-profit study with the aim of evaluating the entity and potential variables influencing the catch-up growth of childhood gluten-free diet patients with celiac disease during a 10-year follow-up. The only extrapolation of the data collected in anonymized form from the medical records of patients who match the necessary study criteria will be planned in order to achieve this aim. A 900-patient sample size will be planned.",[27],"2024-08-15",{"date":465,"type":33},"2024-08-19",{"date":467,"type":33},"2024-07-01",{"date":469,"type":21},"2025-01-01",{"name":471,"class":40},"ASST Fatebenefratelli Sacco",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":479,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":495},"100541029","validation-of-a-new-innovative-method-for-specific-marker-detection-in-celiac-disease-100541029","NCT06324539","Validation of a New Innovative Method for Specific Marker Detection in Celiac Disease","Validation of a New Innovative Method for the Easy Detection of a Disease Specific Marker to Make Prompt Diagnosis of Celiac Disease in All the Clinical Manifestations: a Paediatric Multicenter Study.","Inclusion Criteria:\n\n\\- Patients undergoing an elective esophagogastroduodenoscopy (EGD) for suspected Celiac Disease (CD), eosinophilic esophagitis, autoimmune enteropathy, inflammatory bowel disease, gastritis, gastric or duodenal ulcer, gastroesophageal reflux disease.\n\nExclusion Criteria:\n\n* Bleeding disorders\n* Patients fulfilling the new European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines for diagnosing CD (version 2020) for a serology-based CD diagnosis\n* Subjects in whom intestinal biopsies are not indicated as part of the diagnostic process",{"count":480,"type":21},332,"Celiac disease (CD) is a common auto-immune disorder induced by gluten ingestion in genetically susceptible individuals (HLA-DQ2\u002FDQ8). Gluten induces small-bowel villous atrophy and a specific immune response characterized by the production of CD-autoantibodies against transglutaminase 2 (anti-TG2) and endomysium (EMA). In symptomatic patients with positive-serum antibodies and villous atrophy, the diagnosis of CD is clearcut.\n\nHowever, 10-30% of patients evaluated for suspected CD show only mild histopathologic changes and fluctuating serologic markers, a condition identified as potential CD. In such cases the diagnosis may remain uncertain.\n\nCD-autoantibodies are produced by intestinal B-cells in the early phases of the disease, before their appearance in the serum and when the duodenal mucosa is still normal. Intestinal CD-antibodies (I-CD-abs) are a marker of CD, have a high sensitivity and specificity for CD and identify those patients with potential CD who are at risk of progression to villous atrophy. I-CD-abs can be detected by double immunofluorescence staining on frozen duodenal sections or by using an endomysial antibody assay in the culture medium of duodenal biopsies (EMAbiopsy).\n\nThe diagnostic accuracy of these techniques is comparable as they both have high sensitivity and specificity. However, their implementation in clinical practice is limited because they require both experienced operators and well-equipped laboratories. There is an unmet need: the development of a new simple and effective diagnostic tool that any gastroenterology unit can use in routine diagnostics to ensure a prompt diagnosis in suspected CD patients, who may benefit from a therapy based on gluten-free diet, and to reduce both unnecessary medical investigations and diagnostic delays.\n\nIn order to simplify and shorten times for the detection of these intestinal antibodies, the study aims to substitute the EMAbiopsy assay with a supernatant obtained quickly after mechanical lysis of fresh intestinal biopsy specimen. The obtained samples will be tested with rapid (about 15 minutes) immune-chromatographic anti-TG2 assay (Rapid Intestinal anti-TG2 Assay).",[27],[193,484,485],"Intestinal antibodies","Rapid test","2024-06-12",{"date":488,"type":33},"2024-06-13",{"date":490,"type":33},"2023-10-04",{"date":492,"type":21},"2025-05",{"name":494,"class":40},"IRCCS Burlo Garofolo",4]